重药控股：预计前三季度净利润同比增长22.51%-36.88%

Core Viewpoint - The company expects a significant increase in net profit for the first three quarters of 2025, indicating strong business growth and operational efficiency [1] Financial Performance - The projected net profit for the first three quarters of 2025 is 358 million yuan, representing a year-on-year growth of 22.51% to 36.88%, compared to 292 million yuan in the same period last year [1] - The net profit, excluding non-recurring gains and losses, is expected to be 348 million yuan, with a year-on-year increase of 25.48% to 40.62%, up from 277 million yuan in the previous year [1] - The basic earnings per share are anticipated to be 0.20 yuan, compared to 0.17 yuan in the same period last year [1] Business Development - The company continues to see growth across various segments, including pharmaceuticals, medical devices, traditional Chinese medicine, specialty pharmacies, and emerging businesses [1] - Ongoing improvements in network layout contribute to steady revenue growth [1]